Navigation Links
GSK Announces Revised Product Labels for Serevent® and Advair®
Date:6/2/2010

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent® and Advair®.  The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.  The changes communicated by the FDA reflect class labeling for all LABA containing products and are specific to product labels in the U.S.

GSK will work quickly to implement changes described in the FDA's correspondence and communicate these changes to healthcare providers.  

Advair and Serevent remain important treatment options for appropriate patients with asthma and COPD.

For full FDA announcement click here. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. US Oncology Announces iKnowMed(TM) Technology Platform
2. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
4. Elbit Imaging Ltd. Announces First Quarter Results for 2010
5. CardioGenics Announces Update Regarding Status of Merck Agreement
6. Xanodyne Announces Planned President & CEO Succession
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
11. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... 10, 2016  Oxis International Inc. (OTC/QB: OXIS) announced ... described as a "clinical trial triumph" after one of ... complete cancer remission. Daniel Vallera , ... Cancer Center. --> Daniel Vallera , ... Cancer Center. --> An article on ...
Breaking Medicine Technology:
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... AxoGen, ... market, will report results for the fourth quarter and full year ended December 31, ... host a conference call and webcast for the investment community following the release at ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp ... book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... The book’s publication date is March 16, 2016. A free review copy is ...
(Date:2/10/2016)... Beach, Florida (PRWEB) , ... February 10, 2016 ... ... Country Club) announced that it has been awarded the prestigious Distinguished Emerald Club ... World award program conducted by BoardRoom magazine, one of the most respected trade ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength ... solution that ensures the integrity of biological samples while operating at ultra-high pressures ...
Breaking Medicine News(10 mins):